CYP2D6 multiallelism

[1] GENERAL METHOD FOR ISOLATION OF HIGH MOLECULAR-WEIGHT DNA FROM EUKARYOTES [J]. NUCLEIC ACIDS RESEARCH, 1976, 3 (09) : 2303 - 2308

[2] DEBRISOQUINE OXIDATION POLYMORPHISM - PHENOTYPIC CONSEQUENCES OF A 3-BASE-PAIR DELETION IN EXON 5 OF THE CYP2D6 GENE [J]. PHARMACOGENETICS, 1993, 3 (03): : 123 - 130

[3] An efficient strategy for detection of known and new mutations of the CYP2D6 gene using single strand conformation polymorphism analysis [J]. PHARMACOGENETICS, 1995, 5 (06): : 373 - 384

[4] CHAUBERT P, 1993, BIOTECHNIQUES, V15, P586

[5] DALY AK, 1995, HUM GENET, V95, P337

[6] DALY AK, 1995, UNPUB

[7] DEMORAIS SMF, 1994, MOL PHARMACOL, V46, P594

[8] DEMORAIS SMF, 1994, J BIOL CHEM, V269, P15419

[9] EVERT B, 1994, N-S ARCH PHARMACOL, V350, P434

[10] CLONING AND SEQUENCING OF A NEW NONFUNCTIONAL CYP2D6 ALLELE - DELETION OF T-1795 IN EXON-3 GENERATES A PREMATURE STOP CODON [J]. PHARMACOGENETICS, 1994, 4 (05): : 271 - 274

[1] GENERAL METHOD FOR ISOLATION OF HIGH MOLECULAR-WEIGHT DNA FROM EUKARYOTES [J]. NUCLEIC ACIDS RESEARCH, 1976, 3 (09) : 2303 - 2308

[2] DEBRISOQUINE OXIDATION POLYMORPHISM - PHENOTYPIC CONSEQUENCES OF A 3-BASE-PAIR DELETION IN EXON 5 OF THE CYP2D6 GENE [J]. PHARMACOGENETICS, 1993, 3 (03): : 123 - 130

[3] An efficient strategy for detection of known and new mutations of the CYP2D6 gene using single strand conformation polymorphism analysis [J]. PHARMACOGENETICS, 1995, 5 (06): : 373 - 384

[4] CHAUBERT P, 1993, BIOTECHNIQUES, V15, P586

[5] DALY AK, 1995, HUM GENET, V95, P337

[6] DALY AK, 1995, UNPUB

[7] DEMORAIS SMF, 1994, MOL PHARMACOL, V46, P594

[8] DEMORAIS SMF, 1994, J BIOL CHEM, V269, P15419

[9] EVERT B, 1994, N-S ARCH PHARMACOL, V350, P434

[10] CLONING AND SEQUENCING OF A NEW NONFUNCTIONAL CYP2D6 ALLELE - DELETION OF T-1795 IN EXON-3 GENERATES A PREMATURE STOP CODON [J]. PHARMACOGENETICS, 1994, 4 (05): : 271 - 274